These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29231047)

  • 1. Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    J Comp Eff Res; 2018 Mar; 7(3):209-221. PubMed ID: 29231047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
    Chen S; Peng Z; Wei M; Liu W; Dai Z; Wang H; Mei J; Cheong M; Zhang H; Kuang M
    BMC Cancer; 2018 Apr; 18(1):392. PubMed ID: 29621988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
    Rostambeigi N; Dekarske AS; Austin EE; Golzarian J; Cressman EN
    J Vasc Interv Radiol; 2014 Jul; 25(7):1075-84. PubMed ID: 24861664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib.
    Lucà MG; Nani R; Schranz M; De Giorgio M; Iegri C; Agazzi R; Sala F; Virotta G; Sarti D; Conte G; Pinelli D; Nicora C; Colledan M; Sironi S; Fagiuoli S
    Future Oncol; 2018 Apr; 14(8):727-735. PubMed ID: 29578364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
    Thein HH; Qiao Y; Zaheen A; Jembere N; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
    PLoS One; 2017; 12(10):e0185198. PubMed ID: 29016627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Zhao RC; Zhou J; Wei YG; Liu F; Chen KF; Li Q; Li B
    Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):493-498. PubMed ID: 28992881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis.
    Rognoni C; Ciani O; Sommariva S; Bargellini I; Bhoori S; Cioni R; Facciorusso A; Golfieri R; Gramenzi A; Mazzaferro V; Mosconi C; Ponziani F; Sacco R; Trevisani F; Tarricone R
    BMC Cancer; 2018 Jul; 18(1):715. PubMed ID: 29976149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
    Aly A; Malangone-Monaco E; Noxon V; Henriques C; Benavente F; Kim A
    Curr Med Res Opin; 2020 Nov; 36(11):1813-1823. PubMed ID: 32969741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
    Cai H; Zhang L; Li N; Zheng B; Liu M
    J Comp Eff Res; 2020 Jun; 9(8):553-562. PubMed ID: 32419473
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review.
    Alonso JC; Casans I; González FM; Fuster D; Rodríguez A; Sánchez N; Oyagüez I; Burgos R; Williams AO; Espinoza N
    BMC Gastroenterol; 2022 Jul; 22(1):326. PubMed ID: 35780112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
    Fidelman N; Kerlan RK
    AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug effect analysis of sorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma.
    Xu X; Meng Q
    Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1751-1755. PubMed ID: 30203774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
    Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
    J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
    Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.
    Vadot L; Boulin M; Guiu B; Aho LS; Vourc'h M; Musat A; Hillon P; Lepage C; Guignard MH; Fagnoni P
    J Clin Pharm Ther; 2015 Feb; 40(1):83-90. PubMed ID: 25413186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.